Skip to content

For in vitro research use only. Not for human or animal consumption.

VaultLabs logo

Peptide encyclopedia · Metabolic pathway research

Retatrutide comparison

Multi-receptor agonist peptide (research literature) · Full compound profile

Also see the expanded Retatrutide compound database page with filters, related articles, and catalog links.

All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use.

Retatrutide is a Multi-receptor agonist peptide (research literature). It is not CJC-1295 or Ipamorelin or Tirzepatide or Semaglutide or RETA/CAG. This page separates those catalogue records. It is not stacking advice and not a protocol.

Retatrutide
Multi-receptor agonist peptide (research literature); CAS 2381089-83-2
Not the same record as
CJC-1295, Ipamorelin, Tirzepatide, Semaglutide, RETA/CAG
What decides the vial
Name, nominal fill, and lot number

Retatrutide on its own record

Retatrutide, also designated LY3437943, is a synthetic peptide described in the literature as a single molecule with agonist activity at three receptors: GLP-1, GIP and glucagon. It is an investigational compound in clinical development and is not an approved medicine. VaultLabs supplies retatrutide as a lyophilised reference material for in vitro laboratory research only.

Chemical name: Retatrutide (LY3437943).

Common synonyms: LY3437943, GLP-1/GIP/glucagon triple receptor agonist peptide.

CAS number: 2381089-83-2 (registry entry).

Molecular formula: C221H342N46O68.

GLP-3 RT 5mg (Reta) is the 5 mg lyophilized unit, listed at AED 299 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 10mg (Reta) is the 10 mg lyophilized unit, listed at AED 449 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 15mg (Reta) is the 15 mg lyophilized unit, listed at AED 549 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 20mg (Reta) is the 20 mg lyophilized unit, listed at AED 649 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 30mg (Reta) is the 30 mg lyophilized unit, listed at AED 849 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. GLP-3 RT 100mg (Reta) is the 100 mg lyophilized unit, listed at AED 1,899 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light.

How Retatrutide differs from the linked records

Retatrutide versus CJC-1295. CJC-1295 is a GHRH analog studied in growth hormone secretagogue literature — distinct receptor profile from retatrutide. Retatrutide is listed with CAS 2381089-83-2. No CAS for CJC-1295 is copied onto this page. A certificate for CJC-1295 does not qualify a Retatrutide vial, and the reverse is also true. Read CJC-1295 on its own monograph rather than inferring it from this page.

Retatrutide versus Ipamorelin. Ipamorelin is a selective GHRP-class pentapeptide — compare secretagogue vs multi-agonist literature separately. Retatrutide is listed with CAS 2381089-83-2. No CAS for Ipamorelin is copied onto this page. A certificate for Ipamorelin does not qualify a Retatrutide vial, and the reverse is also true. Read Ipamorelin on its own monograph rather than inferring it from this page.

Retatrutide versus Tirzepatide. Retatrutide is catalogued as a Multi-receptor agonist peptide (research literature). Tirzepatide is catalogued as a Incretin dual-agonist peptide (Metabolic & incretin research). They are separate records. Retatrutide is listed with CAS 2381089-83-2. Tirzepatide is listed with CAS 2023788-19-2. A certificate for Tirzepatide does not qualify a Retatrutide vial, and the reverse is also true. Read Tirzepatide on its own monograph rather than inferring it from this page.

Retatrutide versus Semaglutide. Retatrutide is catalogued as a Multi-receptor agonist peptide (research literature). Semaglutide is catalogued as a Incretin GLP-1 agonist peptide (Metabolic & incretin research). They are separate records. Retatrutide is listed with CAS 2381089-83-2. Semaglutide is listed with CAS 910463-68-2. A certificate for Semaglutide does not qualify a Retatrutide vial, and the reverse is also true. Read Semaglutide on its own monograph rather than inferring it from this page.

Retatrutide versus RETA/CAG. Retatrutide is catalogued as a Multi-receptor agonist peptide (research literature). RETA/CAG is catalogued as a Dual-peptide research blend (Research blends). They are separate records. Retatrutide is listed with CAS 2381089-83-2. RETA/CAG is listed with CAS Not applicable — composite material. A certificate for RETA/CAG does not qualify a Retatrutide vial, and the reverse is also true. Read RETA/CAG on its own monograph rather than inferring it from this page.

Certificates do not cross over

Lot 20280309 for GLP-3 RT 10mg (Reta) is a Freedom Diagnostics report. The published record states 99.94%. Figures printed on the report: Purity (HPLC-UV) 99.94%; Identity (LC-MS) Confirmed; Net content 13.59 mg. Method line on that report: HPLC-UV / LC-MS. The laboratory file is linked from the certificate page. Open GLP-3 RT 10mg (Reta) certificate or match lot 20280309 in batch verification. That report qualifies this lot only.

Lot VL-GLP3-20260317 is the catalogue certificate for GLP-3 RT 10mg (Reta). Read it on GLP-3 RT 10mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.

Lot VL-GLP3RT100-20261020 is the catalogue certificate for GLP-3 RT 100mg (Reta). Read it on GLP-3 RT 100mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.

Lot VL-GLP3RT15-20260917 is the catalogue certificate for GLP-3 RT 15mg (Reta). Read it on GLP-3 RT 15mg (Reta) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.

If a purchase order says Retatrutide, a vial of a related compound does not satisfy it. If the order names a strength, a different strength of Retatrutide does not satisfy it either.

What this comparison refuses to do

It does not rank Retatrutide against another material, recommend a combination, or translate a paper into a dose. VaultLabs does not provide dosage, administration, study-design, or medical guidance.

Prices and the literature notes are on the Retatrutide research summary. Sealed-unit handling is the Retatrutide storage guide. The Retatrutide compound monograph remains the long record.

VaultLabs dispatches Retatrutide from Dubai. Orders leave fulfillment within 24 hours, 7 days a week. Standard delivery is AED 35 to every emirate, and delivery is free when the post-discount merchandise subtotal is AED 500 or more. Checkout shows the fee for the address entered. All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use. VaultLabs does not provide dosage, administration, study-design, or medical guidance.

Questions this page answers

Is Retatrutide the same material as CJC-1295?

No. Retatrutide is a Multi-receptor agonist peptide (research literature). CAS 2381089-83-2. CJC-1295 is a separate catalogue record. Use the monograph for each one.

Can a blend certificate stand in for Retatrutide?

No. A blend that contains Retatrutide, or a similarly named component, has its own lot. That document does not release a single-sequence Retatrutide vial, and a Retatrutide certificate does not release the blend.

Related compounds

Related articles

Research tools

Catalog products

Next recommended reading

All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use.